These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24357333)

  • 1. Urantide conformation and interaction with the urotensin-II receptor.
    Brancaccio D; Limatola A; Campiglia P; Gomez-Monterrey I; Novellino E; Grieco P; Carotenuto A
    Arch Pharm (Weinheim); 2014 Mar; 347(3):185-92. PubMed ID: 24357333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide.
    Grieco P; Carotenuto A; Campiglia P; Gomez-Monterrey I; Auriemma L; Sala M; Marcozzi C; d'Emmanuele di Villa Bianca R; Brancaccio D; Rovero P; Santicioli P; Meini S; Maggi CA; Novellino E
    J Med Chem; 2009 Jul; 52(13):3927-40. PubMed ID: 19432421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insight into the binding mode of peptides at urotensin-II receptor by Trp-constrained analogues of P5U and urantide.
    Carotenuto A; Auriemma L; Merlino F; Limatola A; Campiglia P; Gomez-Monterrey I; di Villa Bianca Rd; Brancaccio D; Santicioli P; Meini S; Maggi CA; Novellino E; Grieco P
    J Pept Sci; 2013 May; 19(5):293-300. PubMed ID: 23526702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.
    Behm DJ; Stankus G; Doe CP; Willette RN; Sarau HM; Foley JJ; Schmidt DB; Nuthulaganti P; Fornwald JA; Ames RS; Lambert DG; Calo' G; Camarda V; Aiyar NV; Douglas SA
    Br J Pharmacol; 2006 May; 148(2):173-90. PubMed ID: 16547525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urotensin-II receptor ligands. From agonist to antagonist activity.
    Grieco P; Carotenuto A; Campiglia P; Marinelli L; Lama T; Patacchini R; Santicioli P; Maggi CA; Rovero P; Novellino E
    J Med Chem; 2005 Nov; 48(23):7290-7. PubMed ID: 16279788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unraveling the active conformation of urotensin II.
    Carotenuto A; Grieco P; Campiglia P; Novellino E; Rovero P
    J Med Chem; 2004 Mar; 47(7):1652-61. PubMed ID: 15027856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urotensin-II receptor peptide agonists.
    Carotenuto A; Grieco P; Novellino E; Rovero P
    Med Res Rev; 2004 Sep; 24(5):577-88. PubMed ID: 15224381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor.
    Carotenuto A; Auriemma L; Merlino F; Yousif AM; Marasco D; Limatola A; Campiglia P; Gomez-Monterrey I; Santicioli P; Meini S; Maggi CA; Novellino E; Grieco P
    J Med Chem; 2014 Jul; 57(14):5965-74. PubMed ID: 24992374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.
    Lescot E; Sopkova-de Oliveira Santos J; Colloc'h N; Rodrigo J; Milazzo-Segalas I; Bureau R; Rault S
    Proteins; 2008 Oct; 73(1):173-84. PubMed ID: 18409194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of urotensin-II receptor structural domains involved in the recognition of U-II, URP, and urantide.
    Boivin S; Guilhaudis L; Milazzo I; Oulyadi H; Davoust D; Fournier A
    Biochemistry; 2006 May; 45(19):5993-6002. PubMed ID: 16681371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-Activity Study of the Peptides P5U and Urantide by the Development of Analogues Containing Uncoded Amino Acids at Position 9.
    Merlino F; Brancaccio D; Yousif AM; Piras L; Campiglia P; Gomez-Monterrey I; Santicioli P; Meini S; Maggi CA; Novellino E; Carotenuto A; Grieco P
    ChemMedChem; 2016 Aug; 11(16):1856-64. PubMed ID: 27061352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships of a novel series of urotensin II analogues: identification of a urotensin II antagonist.
    Chatenet D; Dubessy C; Boularan C; Scalbert E; Pfeiffer B; Renard P; Lihrmann I; Pacaud P; Tonon MC; Vaudry H; Leprince J
    J Med Chem; 2006 Nov; 49(24):7234-8. PubMed ID: 17125276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay.
    Brkovic A; Hattenberger A; Kostenis E; Klabunde T; Flohr S; Kurz M; Bourgault S; Fournier A
    J Pharmacol Exp Ther; 2003 Sep; 306(3):1200-9. PubMed ID: 12807997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, conformational analysis, and biological studies of urotensin-II lactam analogues.
    Grieco P; Carotenuto A; Patacchini R; Maggi CA; Novellino E; Rovero P
    Bioorg Med Chem; 2002 Dec; 10(12):3731-9. PubMed ID: 12413830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta.
    Patacchini R; Santicioli P; Giuliani S; Grieco P; Novellino E; Rovero P; Maggi CA
    Br J Pharmacol; 2003 Dec; 140(7):1155-8. PubMed ID: 14645137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors.
    Camarda V; Song W; Marzola E; Spagnol M; Guerrini R; Salvadori S; Regoli D; Thompson JP; Rowbotham DJ; Behm DJ; Douglas SA; Calo' G; Lambert DG
    Eur J Pharmacol; 2004 Sep; 498(1-3):83-6. PubMed ID: 15363979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An investigation into the origin of the biased agonism associated with the urotensin II receptor activation.
    Brancaccio D; Merlino F; Limatola A; Yousif AM; Gomez-Monterrey I; Campiglia P; Novellino E; Grieco P; Carotenuto A
    J Pept Sci; 2015 May; 21(5):392-9. PubMed ID: 25694247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urotensin receptor antagonist urantide improves atherosclerosis-related kidney injury by inhibiting JAK2/STAT3 signaling pathway in rats.
    Wang T; Xie YQ; Miao GX; Cui HP; Liu K; Li Y; Li Y; Zhao J
    Life Sci; 2020 Apr; 247():117421. PubMed ID: 32061865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803).
    Camarda V; Spagnol M; Song W; Vergura R; Roth AL; Thompson JP; Rowbotham DJ; Guerrini R; Marzola E; Salvadori S; Cavanni P; Regoli D; Douglas SA; Lambert DG; Calò G
    Br J Pharmacol; 2006 Jan; 147(1):92-100. PubMed ID: 16273120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urantide alleviates the symptoms of atherosclerotic rats in vivo and in vitro models through the JAK2/STAT3 signaling pathway.
    Wang T; Xie L; Bi H; Li Y; Li Y; Zhao J
    Eur J Pharmacol; 2021 Jul; 902():174037. PubMed ID: 33891969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.